Search research articles
Contact Us
Filters
Showing results (431-440 of 444) with videos related to
Page
of 45
Sort By:
The New England Journal of Medicine
|
September 2, 2011
A trial of an impedance threshold device in out-of-hospital cardiac arrest
Tom P Aufderheide, Graham Nichol, Thomas D Rea, et al.
The Oncologist
|
January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis
Ogechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology
|
October 21, 2021
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser, Antonio Silvani, Emilie Le Rhun, et al.
Journal of Neuro-Oncology
|
August 5, 2025
The concept, intention, and evaluation of the term treatment-refractory meningioma
Lasse Rehné Jensen, Andrea Daniela Maier, Tareq A Juratli, et al.
Nature Cancer
|
August 19, 2025
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling
Wies R Vallentgoed, Youri Hoogstrate, Karin A van Garderen, et al.
Journal Francais D'Ophtalmologie
|
February 18, 2026
Extension of the intravitreal injection interval after switching to faricimab in patients with exudative AMD: The multicenter FAR WEST study
A Posnic, M Vaast, A Poinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology
|
October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Page
of 45
Search research articles
Search
Showing results (431-440 of 444) with videos related to
Sort By:
Page
of 45
The New England Journal of Medicine
|
September 2, 2011
A trial of an impedance threshold device in out-of-hospital cardiac arrest
Tom P Aufderheide, Graham Nichol, Thomas D Rea, et al.
The Oncologist
|
January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis
Ogechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Neuro-Oncology
|
October 21, 2021
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser, Antonio Silvani, Emilie Le Rhun, et al.
Journal of Neuro-Oncology
|
August 5, 2025
The concept, intention, and evaluation of the term treatment-refractory meningioma
Lasse Rehné Jensen, Andrea Daniela Maier, Tareq A Juratli, et al.
Nature Cancer
|
August 19, 2025
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling
Wies R Vallentgoed, Youri Hoogstrate, Karin A van Garderen, et al.
Journal Francais D'Ophtalmologie
|
February 18, 2026
Extension of the intravitreal injection interval after switching to faricimab in patients with exudative AMD: The multicenter FAR WEST study
A Posnic, M Vaast, A Poinas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2022
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial
C Mircea S Tesileanu, Marc Sanson, Wolfgang Wick, et al.
Lancet (London, England)
|
August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
The Lancet. Oncology
|
October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Page
of 45